-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 22, Sanofi announced that the National Medical Products Administration (NMPA) of China has formally approved Maidarone (dronedarone hydrochloride tablets) for paroxysmal or persistent atrial fibrillation (abbreviated as " Atrial fibrillation") patients with a history of sinus rhythm, reduce the risk of hospitalization due to atrial fibrillation
Atrial fibrillation refers to the loss of the normal rhythm of the atrial beating, which usually manifests as an irregular and rapid heart rate.
As a new type of antiarrhythmic drug, Maidarone is more effective in maintaining sinus rhythm and reducing the recurrence of atrial fibrillation.
Studies have shown that Maidarone is more effective in maintaining sinus rhythm and reducing the recurrence of atrial fibrillation
Reference materials:
[1] Just now | Sanofi's innovative drug for treatment of atrial fibrillation was approved in China.